MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$272,741,816
Free Cash flow
$17,008,939
Unit: Dollar
Positive Cash Flow Breakdown
Maturities of marketable securit...
Accounts payable
Lease liabilities
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Proceeds from issuance of common...
Accrued expenses
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-09-30
2025-06-30
Net loss
30,983,993
-14,964,876
-29,480,012
Depreciation and amortization expense
-167,226
78,840
169,788
Reduction in carrying amount of right-of-use assets
-163,900
87,274
168,386
Intangible asset amortization
-14,633
7,317
14,633
Stock-based compensation expense
-3,036,615
1,456,080
3,217,210
Net accretion of discount on marketable securities
404,723
0
0
Loss on disposal of fixed assets
-
0
-
Prepaid expenses and other current assets
3,085,087
168,824
-2,072,921
Other assets
797,414
-348,790
-454,058
Accounts payable
384,635
-974,893
500,679
Accrued expenses
-6,687,037
2,366,906
-458,170
Lease liabilities
152,307
-84,230
-162,298
Other liabilities
-93,747
-129,619
-23,957
Net cash used in operating activities
17,070,553
-11,977,235
-23,526,762
Purchases of property and equipment
61,614
7,255
11,061
Purchases of marketable securities
71,990,845
0
-
Maturities of marketable securities
9,000,000
0
0
Net cash used in investing activities
-63,052,459
-7,255
-11,061
Proceeds from exercise of stock options
-128,265
136,645
2,055
Proceeds from issuance of common stock under employee stock purchase plan
-251,585
288,018
133,892
Proceeds from issuance of common stock under at-the-market offering, net of issuance costs
-15,020,046
15,020,046
-
Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-Warrant
-
24,998,919
-
Proceeds from issuance of common stock under at-the-market offering, net of issuance costs-Public Offering
-
164,500,006
-
Proceeds from issuance of common stock under at-the-market offering, net of offering expenses
-
-
13,676,667
Proceeds from issuance of common stock through private placement with aventis inc
-
25,000,000
-
Payment of offering and placement costs
-
3,074,898
64,013
Net cash provided by financing activities
-226,759,910
213,192,069
13,748,601
Net decrease in cash and cash equivalents
-272,741,816
201,207,579
-9,789,222
Cash and cash equivalents at beginning of period
227,563,077
36,144,720
-
Cash and cash equivalents at end of period
47,321,566
227,563,077
-
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net loss
$30,983,993
Accounts payable
$384,635
Lease liabilities
$152,307
Net cash used in
operating activities
$17,070,553
Canceled cashflow
$14,450,382
Net decrease in cash
and cash...
-$272,741,816
Canceled cashflow
$17,070,553
Maturities of marketable
securities
$9,000,000
Accrued expenses
-$6,687,037
Prepaid expenses and
other current assets
$3,085,087
Stock-based compensation
expense
-$3,036,615
Other assets
$797,414
Net accretion of
discount on marketable...
$404,723
Depreciation and
amortization expense
-$167,226
Reduction in carrying
amount of right-of-use...
-$163,900
Other liabilities
-$93,747
Intangible asset
amortization
-$14,633
Net cash provided by
financing activities
-$226,759,910
Net cash used in
investing activities
-$63,052,459
Canceled cashflow
$9,000,000
something is missing
-$211,360,014
Proceeds from issuance of
common stock under...
-$15,020,046
Proceeds from issuance of
common stock under...
-$251,585
Proceeds from exercise of
stock options
-$128,265
Purchases of marketable
securities
$71,990,845
Purchases of property and
equipment
$61,614
Buy us a coffee
Immuneering Corp (IMRX)
Immuneering Corp (IMRX)